Astrazeneca Covid-19 Vaccine
- All
- News
- Videos
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
England Great Demands "Apology" For Djokovic, Victim Of Vaccine "Witch-hunt", After AstraZeneca Withdrawal
In 2022, Novak Djokovic was refused entry to Australia over his Covid-19 vaccine status
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
"Sympathy Goes Out...": AstraZeneca Amid Vaccine's Side Effects Concerns
Amid concerns regarding potential side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant on Tuesday reiterated its commitment to patient safety.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
High Hopes For Nasal Covid Vaccines Despite "Disappointing" Trial
Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say.
-
AstraZeneca Nasal Spray Vaccine For Covid Fizzles In Small, Early Trial
AstraZeneca Plc's ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in an early test.
-
AstraZeneca, Given As Booster, Gives Higher Antibodies Against Omicron
AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a th
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
AstraZeneca Booster Significantly Boosts Antibodies Against Omicron
A third dose of AstraZeneca Plc's Covid-19 vaccine significantly boosted neutralizing antibody levels against Omicron, according to lab studies at the University of Oxford.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
England Great Demands "Apology" For Djokovic, Victim Of Vaccine "Witch-hunt", After AstraZeneca Withdrawal
In 2022, Novak Djokovic was refused entry to Australia over his Covid-19 vaccine status
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
"Sympathy Goes Out...": AstraZeneca Amid Vaccine's Side Effects Concerns
Amid concerns regarding potential side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant on Tuesday reiterated its commitment to patient safety.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
High Hopes For Nasal Covid Vaccines Despite "Disappointing" Trial
Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say.
-
AstraZeneca Nasal Spray Vaccine For Covid Fizzles In Small, Early Trial
AstraZeneca Plc's ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in an early test.
-
AstraZeneca, Given As Booster, Gives Higher Antibodies Against Omicron
AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a th
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
AstraZeneca Booster Significantly Boosts Antibodies Against Omicron
A third dose of AstraZeneca Plc's Covid-19 vaccine significantly boosted neutralizing antibody levels against Omicron, according to lab studies at the University of Oxford.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
